# Current controversies in tubal disease, endometriosis, and pelvic adhesion

Jeffrey M. Goldberg, M.D.,[a] Tommaso Falcone, M.D.,[a] and Michael P. Diamond, M.D.[b]

[a] Women's Health Institute, Cleveland Clinic, Cleveland, Ohio; and [b] Department of obstetrics and Gynecology, August University, Augusta, Georgia

Reproductive surgery for proximal and distal tubal occlusion, as well as for reversal of tubal ligation, may be an alternative or an adjunct to IVF. Surgery for adenomyosis and endometriosis, including endometriomas, may be considered for the treatment of infertility and/or pelvic pain but carries the risks of surgical complications and diminished ovarian reserve. A greater understanding of the pathogenesis of postoperative peritoneal adhesion formation is needed to develop more effective preventive measures to optimize the clinical results of surgery. (Fertil Steril® 2019;112:417–25. ©2019 by American Society for Reproductive Medicine.)
**Key Words:** Reproductive surgery, fallopian tube, endometriosis, adenomyosis, peritoneal adhesions

**Discuss:** You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/50039-28456

---

**W**hile many may feel that reproductive surgery should be abandoned as a primary treatment option for enhancing fertility in favor of IVF, a position we strongly disagree with, it is still necessary as a complimentary treatment for optimizing IVF outcomes for patients with hydrosalpinges and select cases of endometriomas and myomas. This paper will defend the role of reproductive surgery even in the face of ever-improving IVF success rates. Specifically, we will discuss tubal surgery and the surgical management of endometriosis and adenomyosis, as well as the need to reduce postoperative adhesion formation, which may compromise the outcomes of all reproductive surgical procedures.

## TUBAL SURGERY

An individualized approach to infertility treatment has been replaced by an "IVF for everything" philosophy. As a result, many reproductive endocrinologists no longer perform reproductive surgery and relegate the treatment of myomas and endometriosis to minimally invasive gynecologic surgeons. However, fertility-enhancing tubal surgery is exclusively the domain of reproductive surgeons with no one to defer to. The following discussion will attempt to make the case against abandoning the surgical management of tubal infertility.

Tubal disease accounts for 25%–35% of infertility, with over half of those cases due to salpingitis. In addition, 10%–25% of tubal infertility occurs at the proximal end (1). Hysterosalpingography (HSG) is the standard test to document tubal patency. However, approximately two thirds of patients with proximal block on HSG are subsequently demonstrated to be patent by repeat HSG or chromotubation at laparoscopy, indicating that the block was due to spasm of the uterotubal ostia or an obstructing plug (2, 3). Hysteroscopic tubal cannulation achieves patency in over 85%, but approximately one third subsequently reocclude. Nearly half of the patients establish an ongoing intrauterine pregnancy (1). A video demonstrating tubal cannulation is available on The Society for Reproductive Surgeons' website (4).

Approximately 25% of women, about 200 million women worldwide, have undergone voluntary sterilization by tubal ligation, with 14% of them regretting their decision. The rate of regret is highest when performed postpartum as well as in younger women (5).

Early attempts at reversal of tubal sterilization with standard macrosurgical techniques were unrewarding. The promotion of microsurgery in the 1970s led to high success rates and remains the gold standard. Initially performed through a full laparotomy incision with an inpatient hospitalization, it is currently accomplished as an outpatient procedure via minilaparotomy. A video demonstrating tubal anastomosis is available on The Society

for Reproductive Surgeons' website (6). It has also been performed laparoscopically with good success in very skilled hands, although it is technically challenging. Robotic assistance has been incorporated to overcome these difficulties. In fact, the world's first fully robotic surgery was reported in 1999 for reversal of sterilization (7). Retrospective comparisons between minilaparotomy and robotic surgery for tubal anastomosis reported that minilaparotomy was quicker and less expensive and had a higher, although nonstatistically significant, pregnancy rate (8). Furthermore, patients much prefer the cosmetic appearance of a minilaparotomy to the multiple robotic incisions (9).

By whatever means the surgeon elects to accomplish tubal anastomosis, it should be considered the first line of treatment to restore fertility for most cases of tubal sterilization. Pregnancy rates of 70%–90% have been reported for women <40 years of age. Even women >40 have a very respectable 33%–50% pregnancy rate (10–16). A retrospective cohort study that compared tubal anastomosis with IVF concluded that the cumulative delivery rate was significantly higher for anastomosis for women <37 years old but that there was no significant difference in women >37. In addition, the cost per delivery was nearly double that for IVF (17). Decision tree models support that the cost of ongoing pregnancy is only higher for tubal reanastomosis compared with IVF when the woman is > 40 years of age (and increased cost for robotic procedures was even accounted for in one analysis) (18). A third study concluded that tubal anastomosis was more cost-effective even for women >40 (19). The current American Society for Reproductive Medicine committee opinion on the role of tubal surgery concluded that there is good evidence to support the recommendation for microsurgical anastomosis for tubal ligation reversal (20).

In addition to being evidence based, tubal anastomosis is also preferred by many patients who wish to avoid the risk of multiple pregnancy and the inconvenience of the "high-tech" IVF process in favor of a one-time minimally invasive procedure that enables them to attempt to conceive naturally each month. Unfortunately, there are few reproductive endocrinologists who still perform tubal anastomosis. The lack of access to tubal anastomosis is unfortunate not only for our patients today but for future generations of patients as reproductive surgery is no longer an integral part of many fellowship training programs. A survey of reproductive endocrinology fellows reported that 43% of them had not performed a tubal anastomosis as the primary surgeon, a number that has almost certainly increased substantially in the 15 years since this publication (21). It is concerning that tubal anastomosis may no longer be a treatment option for restoring fertility after tubal sterilization. This would certainly be a disservice to our patients.

Another tubal surgical procedure that has all but been abandoned is neosalpingostomy for hydrosalpinges. Two meta-analyses established that the presence of hydrosalpinges reduces IVF implantation, pregnancy, and live birth rates by approximately 50% (22, 23). Salpingectomy and proximal tubal ligation were equally effective in restoring IVF success rates for women without hydrosalpinges (24, 25).

While data on neosalpingostomy are limited, reviewing data from five older noncontrolled studies demonstrated that two-thirds of the patients classified as good prognosis conceived an intrauterine pregnancy, while an ectopic pregnancy occurred in only 3. A video demonstrating neosalpingostomy is available on The Society for Reproductive Surgeons' website (26).

Patients classified as moderate or poor prognosis had poor outcomes and are better served with salpingectomy or proximal ligation followed by IVF (27–31). A more recent prospective study compared pregnancy rates in patient with hydrosalpinges treated by bilateral salpingectomy and IVF versus neosalpingostomy (32). Neosalpingostomy patients who underwent IVF conceived at the same rate as those in the salpingectomy group. Overall, approximately half in each group achieved a pregnancy, but half of the neosalpingostomy patients conceived spontaneously.

In summary, appropriately selected patients can benefit from a cost-effective, minimally invasive outpatient procedure and avoid the need for IVF. Many patients would prefer this if given the option.

## SURGERY FOR ENDOMETRIOSIS AND ADENOMYOSIS

Endometriosis is associated with significant quality-of-life and economic burdens on the patient similar to other chronic diseases such as diabetes (33). Health care costs are mainly due to surgery. There are three overlapping phenotypes that we typically encounter during surgery: peritoneal disease (Fig. 1, superficial ovarian and peritoneal disease), ovarian endometrioma, and deeply infiltrating endometriosis (DIE) (34). In a recent randomized controlled trial in patients with uniquely superficial peritoneal disease, excision and ablation showed similar effectiveness for the treatment of pain (Video 1, available online) (35). As with previous studies, ablation of deep lesions is challenged by the proximity to structures such as the ureter that make excision of lesions a more complete approach.

The management of endometriomas is controversial and has changed with new data on the effect of surgery on ovarian reserve. The diagnosis of an endometrioma can often be made preoperatively due to the classic appearance on ultrasonography of a unilocular cyst, low-level echogenicity of the cyst content, and poor vascularization (36). Endometriomas are typically unilateral and are often associated with more extensive disease. Histologically, endometriomas have a fibrotic capsule, with 60% of the inner wall covered with endometriotic tissue. A critical concept for surgical ablation is that the depth of penetration of this tissue is <1.5 mm (37). Surgical excision of an endometrioma is very effective and is associated with a reduced rate of recurrence, reduced symptom recurrence, and increased spontaneous pregnancy rates (odds ratio, 5.1) compared with ablative surgery (38). However, several studies have shown that excision of an endometrioma is associated with decreased ovarian reserve (39–42). It has been proposed that the intrinsic presence of an endometrioma is associated with decreased ovarian reserve with more impact with bilateral endometriomas (43, 44). Histologic studies have also shown decreased follicular

**FIGURE 1**



Superficial ovarian and peritoneal disease.

Goldberg. Current controversies. Fertil Steril 2019.

density in surrounding cortical specimens excised at the time of endometrioma removal (45). One proposed local effect can be attributed to the proinflammatory and oxidative stress observed with an endometrioma.

The observation of postoperative decrease in anti-müllerian hormone (AMH) may be due to inadvertent removal of ovarian tissue or destruction of follicles from excessive use of electrosurgery. The amount of tissue removed increases with endometrioma dimension, use of preoperative suppressive therapy, and perhaps surgeon experience (46–48). Longer follow-up studies have been mixed as to whether there is recovery of ovarian reserve as measured by AMH (39). There are techniques that can be used to decrease injury to the ovary such as minimal use of electrosurgery, precise hemostasis, and use of alternative methods to electrosurgery such as hemostatic agents or suture (34). Although alternative techniques to complete excision have been proposed including a combination of excision and ablation, none have been shown to be superior in terms of recurrence rates and ovarian reserve (49). In summary, it appears that surgical intervention is associated with a decline in AMH with risk factors that may amplify this loss such as bilateral endometriomas, low preoperative AMH levels, excision of normal ovarian tissue with the cyst, and excision of recurrent cysts (42, 50).

Recurrence after surgery is approximately 30% within 2–5 years, with ovarian cycle suppression reducing this risk significantly (51–53). Prolonged use of postoperative suppression with oral contraceptives can decrease the recurrence to between 68% and 90%. The use of GnRH agonists did not offer any additional benefit, and they are not recommended as primary agents (54). The levonorgestrel-releasing intrauterine device is inferior to ovarian suppression in preventing recurrence of endometriomas (55).

If the patient is scheduled for IVF there are no data to support that excising or ablating the cyst improves outcome (56). In fact some studies have observed decreased to no ovarian response to controlled ovarian hyperstimulation (57, 58). According to both the American Society for Reproductive Medicine and European Society of Human Reproduction and Embryology, the only indications for pre-IVF surgery are severe pelvic pain and to improve access to follicles (59, 60).

Surgery for DIE is complex and is associated with surgical risk. The deep lesions can be found in many areas such as bladder, ureters, bowel, and rectocervical/rectovaginal tissue planes. In patients with chronic pelvic pain unresponsive to medical management, conservative fertility-preserving surgery is indicated to relieve symptoms (59). Long-term follow-up of patients with advanced disease has shown persistent improvement in quality of life (61, 62). Surgery for DIE requires a detailed knowledge of the retroperitoneal space. Ablation of lesions will not treat these deep lesions, and therefore excision is necessary. Furthermore, these lesions are often near critical retroperitoneal structures such as ureter, bowel, and bladder that can be injured with deep ablation. The critical concept of conservative surgery is postoperative medical suppressive therapy. Generally, suppressive therapy with oral contraceptive agents or progestins is effective. Newer drugs such as elagolix have not been compared with these standard agents or in the setting of long-term suppressive therapy (63). Furthermore, their mechanism of action is to induce a hypogonadal state as with all GnRH agonists or antagonists. Medical treatment does not improve fertility.

In patients with both infertility and pain, a surgical approach can help both aspects. Spontaneous pregnancies are common but highly dependent on how much normal anatomy is restored at the end of surgery. One approach is to use the endometriosis fertility index (EFI), which quantifies the final anatomic structures to predict the probability of pregnancy and whether the patient should still proceed to IVF. For example, in a study where the EFI was extremely low (EFI score, 0–1), the probability of pregnancy was 0%.

If the EFI score was high (EFI, 9–10), the spontaneous pregnancy rate was 46% at 1 year, 58% at 2 years, and 91% at 5 years (64).

Patients with deep lesions involving the bowel with infertility and pain can be treated with a surgical approach that includes rectal shaving (excision of the bowel lesion without entering the lumen), disc excision, and bowel resection. There are opinions published on which approach is best (37). The size of the lesion, depth of penetration that involves the inner muscularis layer, and multifocal nature of the lesion will determine the approach. Although microscopic endometriosis surrounds the macroscopic endometriosis nodules, removal of visible lesions only is associated with excellent outcomes (65). Short- and long-term postoperative complications such as fistula, pelvic abscess, and bowel dysfunction are not uncommon and must be taken into consideration (66, 67).

In a review of spontaneous conception in infertile women on the effect of radical surgery for rectovaginal and rectosigmoid endometriosis, the weighted pregnancy rate in 11 studies was between 25% and 30% (68). In a separate review of the outcome of IVF in women with untreated DIE with bowel involvement, the pregnancy rate was 29% (95% confidence interval [CI], 20%–37%) (69). In general it seems logical to offer IVF to women who are relatively asymptomatic and are infertile, but in women requiring surgery for symptom control, fertility outcomes are comparable. In a comparative study of women with colorectal endometriosis, if surgery preceded IVF, the cumulative live birth rates after three cycles were, for first-line surgery followed by IVF, 32.7%, 58.9%, and 70.6%, and for first-line IVF, 13%, 24.8%, and 54.9% ($P=.0078$) (70). If the patient proceeds to IVF there appears to be no progression of disease or recurrence from the ovarian stimulation (71). The use of the robot for endometriosis surgery does not improve outcomes over conventional laparoscopic surgery (72). There are no published clinical trials that suggest the use of fluorescent dye such as indocyanine green improves outcome, although it may identify occult endometriosis not seen by white light (73).

Adenomyosis is characterized by the presence of endometrial-like glands and stroma within the myometrium. The glandular pockets can be diffuse or localized. The pathophysiology of adenomyosis is unclear, but several theories have been proposed such as invasion of the endometrial basalis layer into the myometrium, metaplasia of pluripotent Müllerian rests, or de novo formation from adult stem cells from the endometrial basalis or bone marrow (74). Historically the diagnosis was only confirmed at histology after hysterectomy. Recently, imaging has been more accurate in detecting the presence of adenomyosis. Prevalence data from these two modalities only reflect its occurrence in symptomatic women. Symptoms associated with adenomyosis include abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and dyspareunia. Adenomyosis is frequently seen with endometriosis, especially DIE, as well as with fibroids. The relationship with infertility is unclear, although there may be an increase in miscarriage rates after IVF (75). Imaging modalities such as ultrasonography with the three-dimensional mode have demonstrated the characteristic features of enlarged globular uterus, asymmetry of the myometrium, thickened heterogenous myometrium, and myometrial cysts. The accuracy of diagnosis with ultrasound is reported to be 72% (95% CI, 65%–79%) with a specificity of 81% (95% CI, 77%–85%). Magnetic resonance imaging is reported to have more sensitivity and specificity; these are reported to be 77% (95% CI, 67%–85%) and 89% (95% CI, 67%–85%), respectively (76). Medical management consists of nonsteroidal anti-inflammatory drugs (NSAIDS) and suppressive medical therapy such as oral contraceptives, progestins, levonorgestrol-releasing intrauterine devices, and GnRH agonists. Invariably symptoms recur after discontinuing the medication. Suppressive therapy is recommended after surgical intervention (77). Long-term suppressive therapy with GnRH agonists before IVF has also been shown to improve outcomes (78).

Conservative surgery for the treatment of adenomyosis is indicated in women with severe symptoms unresponsive to medical management who wish to preserve their fertility. It is unclear whether surgical intervention solely to improve fertility is effective. The typical approach to surgical intervention is a wedge resection of an adenomyoma or myometrial thickened area (79). The main concept is that there are no tissue planes and adenomyosis tissue will be left on the sides of the incision. The techniques for hemostasis during adenomyosis resection are similar to those during myomectomy. This surgery can be performed by laparoscopy or by laparotomy. A more radical approach for extensive diffuse adenomyosis is the use of incisions and dissection where serosal and muscular flaps are created with separation and excision of the diseased myometrium with subsequent closure of the serosal and muscular flaps. This surgery can be performed by laparotomy or by minimally invasive techniques depending on the experience of the surgeon. Most of the world literature of over 2,000 surgeries using a more radical approach is from Japan. Surgeons there have reported over 400 pregnancies with 13 cases of uterine rupture (3.6%) (79).

The evolution of the management of endometriosis has been to decrease surgical intervention for both ovarian and nonovarian disease for women with infertility as the sole indication. A decade ago, excision of endometriomas in an infertile patient before IVF was commonplace. Increasingly this is no longer the approach. The evidence is clear that a cystectomy may decrease ovarian reserve. In general, the cyst should be left alone. In patients who have surgery for pain and infertility, the excision of the cyst should be more conservative if the final outcome of the surgery does not establish a normally functioning tube-ovarian anatomy and the patient has a high probability of requiring IVF. In fact, the deeply infiltrating disease under the ovary may be primarily responsible for the pain and should be excised. The cyst should mostly be left alone.

The evolution of the management of deeply infiltrating disease requires experienced surgeons. Many centers now offer a safe surgical approach for excision of this disease, and these centers will continue to expand. There are long-term consequences, but the outcome for management of pain and quality of life is excellent. The controversy about whether we should excise DIE before IVF will continues, but we suspect that a noninterventional approach will be

primarily offered to most patients with infertility as the primary issue.

The surgical approach to adenomyosis is mostly in a state of flux. Few centers offer an integrated surgical approach, and few surgeons have much experience, especially for diffuse adenomyosis. It is not clear which patient would benefit from the surgery. Most importantly, it is not clear what the obstetrical outcome would be when removing a large volume of myometrium. If there were nonsurgical interventions, we predict these would be readily accepted.

## ADHESION PREVENTION

Postoperative adhesion formation has been the bane of nearly every surgical specialty. Even in the most skilled hands, pelvic surgery may lead to postoperative peritoneal adhesion formation. These adhesions may result in infertility, pelvic pain, and bowel obstruction as well as increase the risk for intraoperative complications with subsequent surgeries. Thus, it is imperative that effective methods are devised to reduce postoperative adhesions without compromising normal healing. Although there has been no lack of ingenuity during the past century, achieving this goal remains elusive.

Unchanged during the past decade is the clinical recognition of just how often intraperitoneal/pelvic adhesions develop after gynecological surgical procedures. In fact, prior studies demonstrated the high frequency of adhesion development after surgeries performed by laparotomy or laparoscopy (Table 1) (80–93). Also unchanged is the continued belief in the principles of gynecologic microsurgery as the leading approach to limit postoperative adhesion development (94). However, in view of the high frequency with which adhesions develop as just noted, approaches beyond attention to surgical technique are needed.

Efforts to improve the efficacy of reduction or elimination of postoperative adhesion development are dependent on at least a high-level understanding of normal peritoneal healing, as well as what goes awry when adhesions develop (95–97). After surgical tissue injury, there is release of histamine, cytokines, and growth factors, as well as leakage of blood and lymphatic fluid. These biologic changes initiate an inflammatory-like reaction, with recruitment of inflammatory cells and fibroblasts (including myofibroblasts). Simultaneously, the tissue injury results in vascular disruption, diminishing both the delivery of oxygen and nutrients (creating a state of increasing oxidative stress) and removal of metabolic waste products (contributing to a buildup of lactic acid from anaerobic metabolism, with resultant reduction of tissue pH and associated disruption of enzyme function). Additionally, the collection of blood and lymphatic fluid results in development of a serosanguinous mass at the site of tissue injury, the ultimate fate of which is in part determined by the rate of collection and the fibrinolytic potential in fibroblasts and mesothelial cells (which is itself a function of tissue perfusion, with fibrinolytic potential reduced under hypoxic conditions). Of course, modulation of each of these processes occurs and can contribute to ultimate resolution of the fibrosis mass and reperitonealization without adhesion development. Alternatively, if fibrinolysis is impaired, the fibrinous mass persists and fibroblasts that are drawn to the sites of tissue injury invade the fibrinous mass, with subsequent deposition of collagens and other forms of extracellular matrix with reperitonealization over the fibroblast-invaded fibrinous mass and consequent adhesion development. Importantly, after surgical tissue injury, this process is expected to be completed within 3–5 days (unless ongoing tissue injury persists); this thus represents the window of time for approaches to reduce or prevent adhesion development. Of note, if an adhesion has developed, it will "mature" over time with remodeling (with a greater likelihood of becoming dense and opaque) and vascular in-growth. The latter can teleologically be thought of as the body trying to reestablish a supply of oxygen and nutrients to hypoxic tissue, as likely occurs with all healing processes.

Importantly, our understanding of the pathogenesis of pelvic adhesions has expanded upon prior observations of the key role of the extent and degree of tissue injury having a direct correlation with the likelihood of adhesion development (98). The new understanding is that the impact of tissue injury is reflected in the occurrence of oxidative stress, as evidenced by generation of reactive oxygen and reactive nitrogen species (99). A corollary is that adhesion development is likely highly influenced by the metabolic state, with adhesions more likely in the presence of an anaerobic (hypoxic) state (100, 101).

Of note, in addition to these classic factors associated with adhesion development, the potential for the impact of nonclassic factors is becoming increasingly recognized as well (102). Devices currently approved for reduction of postoperative adhesions predate the past decade. The first product to receive FDA approval for reduction of postoperative adhesion was Interceed (80) (oxidized regenerated cellulose, Johnson and Johnson) in 1989. Other products currently approved by the U.S. FDA are Seprafilm (83) (modified hyaluronic acid and carboxymethylcellulose, Genzyme [now Sanofi]) in 1996 and Adept (82) (4% icodextrin solution, Baxter) in 2006. There have been no new adjuvants approved for use in the United States for reduction of postoperative adhesions in the past decade.

There may also be an opportunity to better understand factors important for adhesion development to the uterus in nonpregnant (e.g., myomectomy) and pregnant (e.g., cesarean section) states. Multiple reports have identified that in the absence of an antiadhesion adjuvant after posterior myomectomy, adhesions to the uterus frequently occur in most women in procedures performed at laparotomy (83, 103) and laparoscopy (91, 93). In contrast, uterine adhesion development after an initial cesarean section is considerably less (104) (although repeat cesarean section is associated with dramatic increases in adhesion development). There are multiple potential differences in uterine healing in the pregnant and nonpregnant states that may contribute to these differences in the frequency of adhesion occurrences (105). These include increased uterine blood flow after pregnancy (with potential impact on nutrient and oxygen delivery and metabolic waste removal, influencing the oxidative state), mechanical processes involving the pregnant uterus such as uterine involution; incision

## TABLE 1

Adhesion incidence after intra-abdominal use of antiadhesion adjuvants in humans.

| Author (ref) | Lap/scope | Site | Treatment control | Adhesion incidence | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | | | No. of sites | Total sites | % |
| Azziz (80) | Lap | Pelvic sidewall | Interceed | 66 | 134 | 49.3 |
| | | | No treatment | 102 | 134 | 76.1 |
| Franklin (86) | Lap | Ovary | Interceed | 29 | 55 | 52.7 |
| | | | No treatment | 41 | 55 | 74.5 |
| Nordic (90) | Lap | Adnexae | Interceed | 96 | 198 | 49.5 |
| | | | No treatment | 140 | 198 | 70.7 |
| Sekiba (92) | Lap | Pelvic sidewall | Interceed | 23 | 63 | 41 |
| | | | No treatment | 48 | 63 | 76 |
| Li (87) | Lap | Pelvic adhesions | Interceed | 17 | 27 | 63 |
| | | | No treatment | 20 | 27 | 74 |
| Diamond (84) | Lap | Abdominal pelvic Cavity[a] | Sepracoat (hyaluronic acid) | 119 | 137 | 86.9 |
| | | | No treatment | 103 | 108 | 95.4 |
| Diamond (83) | Lap | Anterior uterus[b] | Seprafilm | | | 61 |
| | | Posterior uterus | No treatment | | | 94 |
| | | | Seprafilm | | 59 | 87 |
| | | | No treatment | | 68 | 92 |
| Becker (81) | Lap | Anterior abdominal wall | Seprafilm | 42 | 85 | 49 |
| | | | No treatment | 85 | 90 | 94 |
| Mettler (89) | Combination | Uterus | Spraygel | 15 | 22 | 68.2 |
| | | | No treatment | 16 | 18 | 88.9 |
| DiZerega (85) | Scope | Abdominal pelvic cavity[c] | Adept (icodextrin) | 15 | 22 | 68.2 |
| | | | LRS | 12 | 17 | 70.6 |
| Brown (82) | Scope | Abdominal pelvic cavity[a] | Adept (icodextrin) | | 203 | 47 |
| | | | LRS | | 199 | 57 |
| Mais (88) | Scope | Uterus | Hyalobarrier | 8 | 21 | 38 |
| | | | No treatment | 13 | 22 | 41 |
| Pellicano (91) | Scope | Uterus | Hyalobarrier | 5 | 18 | 27.8 |
| | | | No treatment | 14 | 18 | 77.8 |
| Takeuchi (93) | Scope | Uterus | Fibrin gel | 10 | 29 | 34.5 |
| | | | Fibrin sheet | 20 | 30 | 67.7 |
| | | | No treatment | 20 | 32 | 62.5 |

*Note:* Interceed is oxidized regenerated cellulose; Sepracoat is 4% hyaluronic acid; Seprafilm is modified hyaluronic acid and carboxymethycellulose; Spraygel is polyethylene glycol; Hyalobarrier is crosslinked hyaluronic acid; and Adept is 4% Icodextrin. Lap = laparotomy; scope = laparoscopy; LRS = lactated ringer solution.
[a] De novo adhesion.
[b] With at least one anterior uterine incision.
[c] Reformed adhesions.

*Goldberg. Current controversies. Fertil Steril 2019.*

location, which in the pregnant uterus is often the lower uterine segment, which is overlain by the filling and emptying bladder; and the hypercoagulable state in pregnancy. Understanding of the role of these factors in adhesion development may help provide approaches to limit postoperative adhesion development in the future.

The past decade has seen increasing suggestion that alterations to surgical procedures could have a favorable impact on reducing postoperative adhesion development. Foremost has been the concept that performance of procedures by laparoscopy per se, as opposed to laparotomy, will reduce occurrence of adhesions. While this claim predates the past decade, it continues to be difficult to conclusively prove in humans, likely because of the difficulty in testing this hypothesis because of the requirements for designing and conducting conclusive trials. The simple idea that laparoscopy is associated with less tissue drying and less cooling of tissue, and thus results in reduced tissue damage, is confounded by animal studies that demonstrate that laparoscopic insufflation alone can induce adhesion development, in a manner that is dependent on the time, insufflation gas volume, and pressure (106–109). The recent creation of insufflators, which deliver warmed and humidified gas, provide the opportunity to examine the impact on the creation of peritoneal oxidative stress and subsequent adhesion development.

An alternative (although not necessarily mutually exclusive) approach to the prevention of adhesion development between a site of surgery and an adjacent organ is to separate the structures during the healing process, which as noted earlier for the peritoneum, is thought to take no more than 3–5 days. Instead of using a barrier on the injured surface (or in addition to the use of a barrier), there is the option to mechanically hold a structure away from the healing surface. A specific situation where this approach has been used is temporary ovarian suspension, to keep the ovary separate from the pelvic sidewall and other pelvic structures. Descriptive studies suggest this may be of benefit (110), although well-designed studies to more definitively assess the value of temporary ovarian suspension are needed.

In summary, prevention of postoperative development is likely one of the greatest unmet needs in surgery today. While the past decade has solidified our understanding of factors important to the pathogenesis of adhesion development, and new molecular biologic and clinical observations have

added to this understanding, there remains a major unmet need to fully understand adhesion pathogenesis. A major challenge that has limited progress to date is the biologic similarity between "desired" healing, such as closure of the abdominal wall, the peritoneum, and organs (such as the uterus after myomectomy and the ovary after cystectomy), and adhesions development. Identification of differences in the molecular process involved, between desired healing and adhesion development, will likely be key to the initiation of targeted therapies to prevent development of adhesions.

Lastly, a challenge in the past decade has been the widespread recognition not only by the public, but also by surgeons, hospital officials, and insurance administrators, of the high frequency of postoperative adhesions development and the devastating morbidity they can cause years or decades later. Recognition of these basic facts will undoubtedly result in greater use of antiadhesion adjuvants, as well as other approaches to reduce postoperative adhesions. However, the current health care policies/systems in the United States also may be a factor in the low use of these products, as officials/administrators may be responding more to current expenses as opposed to health outcomes years later, when care providers, location of care, and health insurance may differ from those at the time of the surgical procedure. Although the last decade has not yielded definitive long-term economic assessments, there have been attempts at economic modeling that do demonstrate a societal economic benefit to the use of antiadhesion adjuvants (111, 112).

# REFERENCES

1. Honoré GM, Holden AE, Schenken RS. Pathophysiology and management of proximal tubal blockage. Fertil Steril 1999;71:785–95.
2. Dessole S, Meloni GB, Capobianco G, Manzoni MA, Ambrosini G, Canalis GC. A second hysterosalpingography reduces the use of selective technique for treatment of a proximal tubal obstruction. Fertil Steril 2000;73:1037–9.
3. Evers JLH, Land JA, Mol BW. Evidence-based medicine for diagnostic questions. Semin Reprod Med 2003;21:9–15.
4. Goldberg JM. Hysteroscopic tubal cannulation. Available at: https://www.reprodsurgery.org/Go.aspx?MicrositeGroupTypeRouteDesignKey=70e4f361-c572-4bb7-8218-8d0f32b6b254&NavigationKey=4f1701e4-b1bf-497a-9288-c78a17569cd3.
5. Schmidt JE, Hillis SD, Marchbanks PA, Jeng G, Peterson HB. Requesting information about and obtaining reversal after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Fertil Steril 2000;74:892–8.
6. Goldberg JM. Tubal anastomosis. Available at: https://www.reprodsurgery.org/Go.aspx?MicrositeGroupTypeRouteDesignKey=70e4f361-c572-4bb7-8218-8d0f32b6b254&NavigationKey=d46e2edd-5ce7-4b27-9f07-e6ba687578a8.
7. Falcone T, Goldberg J, Garcia-Ruiz A, Margossian H, Stevens L. Full robotic assistance for laparoscopic tubal anastomosis: a case report. J Laparoendosc Adv Surg Tech A 1999;9:107–13.
8. Rodgers AK, Goldberg JM, Hammel JP, Falcone T. Tubal anastomosis by robotic compared with outpatient minilaparotomy. Obstet Gynecol 2007;109:1375–80.
9. Goebel K, Goldberg JM. Women's preference of cosmetic results after gynecologic surgery. J Minim Invasive Gynecol 2014;21:64–7.
10. Berger GS, Thorp JM, Weaver MA. Effectiveness of bilateral tubotubal anastomosis in a large outpatient population. Hum Reprod 2016;31:1120–5.
11. Cha SH, Lee MH, Kim JH, Lee CN, Yoon TK, Cha KY. Fertility outcome after tubal anastomosis by laparoscopy and laparotomy. J Am Assoc Gynecol Laparosc 2001;8:348–52.
12. Dubuisson JB, Chapron C, Nos C, Morice P, Aubriot FX, Garnier P. Sterilization reversal: fertility results. Hum Reprod 1995;10:1145–51.
13. Gordts S, Campo R, Puttemans P, Gordts S. Clinical factors determining pregnancy outcome after microsurgical tubal reanastomosis. Fertil Steril 2009;92:1198–202.
14. Kim JD, Kim KS, Doo JK, Rhyeu CH. A report on 387 cases of microsurgical tubal reversals. Fertil Steril 1997;68:875–80.
15. Petrucco OM, Silber SJ, Chamberlain SL, Warnes GM, Davies M. Live birth following day surgery reversal of female sterilisation in women older than 40 years: a realistic option in Australia? Med J Aust 2007;187:271–3.
16. Trimbos-Kemper TC. Reversal of sterilization in women over 40 years of age: a multicenter survey in The Netherlands. Fertil Steril 1990;53:575–7.
17. Boeckxstaens A, Devroey P, Collins J, Tournaye H. Getting pregnant after tubal sterilization: surgical reversal or IVF? Hum Reprod 2007;22:2660–4.
18. Messinger LB, Alford CE, Csokmay JM, Henne MB, Mumford SL, Segars JH, et al. Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation. Fertil Steril 2015;104:32–8.e4.
19. Hirshfeld-Cytron J, Winter J. Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis. Am J Obstet Gynecol 2013;209:56.e1–6.
20. Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertil Steril 2015;103:e37–43.
21. Armstrong A, Neithardt AB, Alvero R, Sharara FI, Bush M, Segars J. The role of fallopian tube anastomosis in training fellows: a survey of current reproductive endocrinology fellows and practitioners. Fertil Steril 2004;82:495–7.
22. Camus E, Poncelet C, Goffinet F, Wainer B, Merlet F, Nisand I, et al. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Hum Reprod 1999;14:1243–9.
23. Strandell A, Lindhard A, Waldenström U, Thorburn J, Janson PO, Hamberger L. Hydrosalpinx and IVF outcome: a prospective, randomized multicentre trial in Scandinavia on salpingectomy prior to IVF. Hum Reprod 1999;14:2762–9.
24. Johnson N, van Voorst S, Sowter MC, Strandell A, Mol BWJ. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev 2010:CD002125.
25. Xu B, Zhang Q, Zhao J, Wang Y, Xu D, Li Y. Pregnancy outcome of in vitro fertilization after Essure and laparoscopic management of hydrosalpinx: a systematic review and meta-analysis. Fertil Steril 2017;108:84–95.e5.
26. Goldberg JM. Neosalpingostomy. Available at: https://www.reprodsurgery.org/Go.aspx?MicrositeGroupTypeRouteDesignKey=70e4f361-c572-4bb7-8218-8d0f32b6b254&NavigationKey=4f1701e4-b1bf-497a-9288-c78a17569cd3.
27. Boer-Meisel ME, te Velde ER, Habbema JD, Kardaun JW. Predicting the pregnancy outcome in patients treated for hydrosalpinx: a prospective study. Fertil Steril 1986;45:23–9.
28. Donnez J, Casanas-Roux F. Prognostic factors of fimbrial microsurgery. Fertil Steril 1986;46:200–4.
29. Oh ST. Tubal patency and conception rates with three methods of laparoscopic terminal neosalpingostomy. J Am Assoc Gynecol Laparosc 1996;3:519–23.
30. Rock JA, Katayama KP, Martin EJ, Woodruff JD, Jones HW. Factors influencing the success of salpingostomy techniques for distal fimbrial obstruction. Obstet Gynecol 1978;52:591–6.
31. Schlaff WD, Hassiakos DK, Damewood MD, Rock JA. Neosalpingostomy for distal tubal obstruction: prognostic factors and impact of surgical technique. Fertil Steril 1990;54:984–90.

32. Chanelles O, Ducarme G, Sifer C, Hugues J-N, Touboul C, Poncelet C. Hydrosalpinx and infertility: what about conservative surgical management? Eur J Obstet Gynecol Reprod Biol 2011;159:122–6.

33. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012;27:1292–9.

34. Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol 2018;131:557–71.

35. Riley KA, Benton AS, Deimling TA, Kunselman AR, Harkins GJ. Surgical excision versus ablation for superficial endometriosis-associated pain: a randomized controlled trial. J Minim Invasive Gynecol 2019;26:71–7.

36. Exacoustos C, Zupi E, Piccione E. Ultrasound imaging for ovarian and deep infiltrating endometriosis. Semin Reprod Med 2017;35:5–24.

37. Muzii L, Bianchi A, Bellati F, Cristi E, Pernice M, Zullo MA, et al. Histologic analysis of endometriomas: what the surgeon needs to know. Fertil Steril 2007;87:362–6.

38. Hart RJ, Hickey M, Maouris P, Buckett W. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev 2008: CD004992.

39. Alborzi S, Keramati P, Younesi M, Samsami A, Dadras N. The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Fertil Steril 2014;101:427–34.

40. Goodman LR, Goldberg JM, Flyckt RL, Gupta M, Harwalker J, Falcone T. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol 2016;215:589.e1–6.

41. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:3146–54.

42. Somigliana E, Berlanda N, Benaglia L, Viganò P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril 2012; 98:1531–8.

43. Nieweglowska D, Hajdyla-Banas I, Pitynski K, Banas T, Grabowska O, Juszczyk G, et al. Age-related trends in anti-Mullerian hormone serum level in women with unilateral and bilateral ovarian endometriomas prior to surgery. Reprod Biol Endocrinol 2015;13:128.

44. Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod 2013;28:2140–5.

45. Kitajima M, Defrère S, Dolmans M-M, Colette S, Squifflet J, van Langendonckt A, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril 2011;96:685–91.

46. Matsuzaki S, Houlle C, Darcha C, Pouly J-L, Mage G, Canis M. Analysis of risk factors for the removal of normal ovarian tissue during laparoscopic cystectomy for ovarian endometriosis. Hum Reprod 2009;24:1402–6.

47. Muzii L, Marana R, Angioli R, Bianchi A, Cucinella G, Vignali M, et al. Histologic analysis of specimens from laparoscopic endometrioma excision performed by different surgeons: does the surgeon matter? Fertil Steril 2011;95:2116–9.

48. Roman H, Tarta O, Pura I, Opris I, Bourdel N, Marpeau L, et al. Direct proportional relationship between endometrioma size and ovarian parenchyma inadvertently removed during cystectomy, and its implication on the management of enlarged endometriomas. Hum Reprod 2010;25: 1428–32.

49. Muzii L, Achilli C, Bergamini V, Candiani M, Garavaglia E, Lazzeri L, et al. Comparison between the stripping technique and the combined excisional/ablative technique for the treatment of bilateral ovarian endometriomas: a multicentre RCT. Hum Reprod 2016;31:339–44.

50. Ferrero S, Scala C, Racca A, Calanni L, Remorgida V, Venturini PL, et al. Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study. Fertil Steril 2015;103:1236–43.

51. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Montanari G, Keramyda A, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril 2010;93:52–6.

52. Takamura M, Koga K, Osuga Y, Takemura Y, Hamasaki K, Hirota Y, et al. Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Hum Reprod 2009;24: 3042–8.

53. Vercellini P, Somigliana E, Viganò P, de Matteis S, Barbara G, Fedele L. Postoperative endometriosis recurrence: a plea for prevention based on pathogenetic, epidemiological and clinical evidence. Reprod Biomed Online 2010;21:259–65.

54. Vercellini P, De Matteis S, Somigliana E, Buggio L, Frattaruolo MP, Fedele L. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013;92:8–16.

55. Chen Y-J, Hsu T-F, Huang B-S, Tsai H-W, Chang Y-H, Wang P-H. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol 2017;216:582.e1–9.

56. Demirol A, Guven S, Baykal C, Gurgan T. Effect of endometrioma cystectomy on IVF outcome: a prospective randomized study. Reprod Biomed Online 2006;12:639–43.

57. Nickkho-Amiry M, Savant R, Majumder K, Edi-O'sagie E, Akhtar M. The effect of surgical management of endometrioma on the IVF/ICSI outcomes when compared with no treatment? A systematic review and meta-analysis. Arch Gynecol Obstet 2018;297:1043–57.

58. Tao X, Chen L, Ge S, Cai L. Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: a meta-analysis. PLoS One 2017;12:e0177426.

59. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400–12.

60. Practice Committee of the American Society for Reproductive Medicine. Committee opinion: role of tubal surgery in the era of assisted reproductive technology. Fertil Steril 2012;97:539–45.

61. Comptour A, Chauvet P, Canis M, Grémeau A-S, Pouly J-L, Rabischong B, et al. Patient quality of life and symptoms after surgical treatment for endometriosis. J Minim Invasive Gynecol 2019;26:717–26.

62. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008;111:1285–92.

63. Vercellini P, Viganò P, Barbara G, Buggio L, Somigliana E, 'Luigi Mangiagalli' Endometriosis Study Group. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod 2019;34:193–9.

64. Maheux-Lacroix S, Nesbitt-Hawes E, Deans R, Won H, Budden A, Adamson D, et al. Endometriosis fertility index predicts live births following surgical resection of moderate and severe endometriosis. Hum Reprod 2017;32:2243–9.

65. Badescu A, Roman H, Barsan I, Soldea V, Nastasia S, Aziz M, et al. Patterns of bowel invisible microscopic endometriosis reveal the goal of surgery: removal of visual lesions only. J Minim Invasive Gynecol 2018;25:522–7.e9.

66. Abo C, Moatassim S, Marty N, Saint Ghislain M, Huet E, Bridoux V, et al. Postoperative complications after bowel endometriosis surgery by shaving, disc excision, or segmental resection: a three-arm comparative analysis of 364 consecutive cases. Fertil Steril 2018;109:172–8.e1.

67. Soto E, Catenacci M, Bedient C, Jelovsek JE, Falcone T. Assessment of long-term bowel symptoms after segmental resection of deeply infiltrating endometriosis: a matched cohort study. J Minim Invasive Gynecol 2016; 23:753–9.

68. Berlanda N, Vercellini P, Somigliana E, Frattaruolo MP, Buggio L, Gattei U. Role of surgery in endometriosis-associated subfertility. Semin Reprod Med 2013;31:133–43.

69. Cohen J, Thomin A, Mathieu D'Argent E, Laas E, Canlorbe G, Zilberman S, et al. Fertility before and after surgery for deep infiltrating endometriosis with and without bowel involvement: a literature review. Minerva Ginecol 2014;66:575–87.

70. Bendifallah S, Roman H, Mathieu d'Argent E, Touleimat S, Cohen J, Darai E, et al. Colorectal endometriosis-associated infertility: should surgery precede ART? Fertil Steril 2017;108:525–31.e4.

71. Somigliana E, Viganò P, Benaglia L, Busnelli A, Paffoni A, Vercellini P. Ovarian stimulation and endometriosis progression or recurrence: a systematic review. Reprod Biomed Online 2019;38:185–94.

72. Soto E, Luu TH, Liu X, Magrina JF, Wasson MN, Einarsson JI, et al. Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a multicenter, randomized, controlled trial. Fertil Steril 2017;107:996–1002.e3.

73. Cosentino F, Vizzielli G, Turco LC, Fagotti A, Cianci S, Vargiu V, et al. Near-infrared imaging with indocyanine green for detection of endometriosis lesions (Gre-Endo Trial): a pilot study. J Minim Invasive Gynecol 2018;25:1249–54.

74. García-Solares J, Donnez J, Donnez O, Dolmans M-M. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril 2018;109:371–9.

75. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014;29:964–77.

76. Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. Acta Obstet Gynecol Scand 2010;89:1374–84.

77. Wang P-H, Liu W-M, Fuh J-L, Cheng M-H, Chao H-T. Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril 2009;92:876–85.

78. Vannuccini S, Luisi S, Tosti C, Sorbi F, Petraglia F. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018;109:398–405.

79. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril 2018;109:406–17.

80. Azziz R. Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II. Surg Gynecol Obstet 1993;177:135–9.

81. Becker JM, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg 1996;183:297–306.

82. Brown CB, Luciano AA, Martin D, Peers E, Scrimgeour A, diZerega GS, et al. Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. Fertil Steril 2007;88:1413–26.

83. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril 1996;66:904–10.

84. Diamond MP. Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group. Fertil Steril 1998;69:1067–74.

85. diZerega GS, Verco SJS, Young P, Kettel M, Kobak W, Martin D, et al. A randomized, controlled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions following laparoscopic gynaecological surgery. Hum Reprod 2002;17:1031–8.

86. Franklin RR. Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhesion Study Group. Obstet Gynecol 1995;86:335–40.

87. Li TC, Cooke ID. The value of an absorbable adhesion barrier, Interceed, in the prevention of adhesion reformation following microsurgical adhesiolysis. Br J Obstet Gynaecol 1994;101:335–9.

88. Mais V, Bracco GL, Litta P, Gargiulo T, Melis GB. Reduction of postoperative adhesions with an auto-crosslinked hyaluronan gel in gynaecological laparoscopic surgery: a blinded, controlled, randomized, multicentre study. Hum Reprod 2006;21:1248–54.

89. Mettler L, Audebert A, Lehmann-Willenbrock E, Schive-Peterhansl K, Jacobs VR. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil Steril 2004;82:398–404.

90. Nordic Adhesion Prevention Study Group. The efficacy of Interceed(TC7)* for prevention of reformation of postoperative adhesions on ovaries, fallopian tubes, and fimbriae in microsurgical operations for fertility: a multicenter study. Fertil Steril 1995;63:709–14.

91. Pellicano M, Bramante S, Cirillo D, Palomba S, Bifulco G, Zullo F, et al. Effectiveness of autocrosslinked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study. Fertil Steril 2003;80:441–4.

92. Sekiba K. Use of Interceed(TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. Obstet Gynecol 1992;79:518–22.

93. Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Kinoshita K. Adhesion-prevention effects of fibrin sealants after laparoscopic myomectomy as determined by second-look laparoscopy: a prospective, randomized, controlled study. J Reprod Med 2005;50:571–7.

94. Gomel V, Koninckx PR. Microsurgical principles and postoperative adhesions: lessons from the past. Fertil Steril 2016;106:1025–31.

95. Awonuga AO, Belotte J, Abuanzeh S, Fletcher NM, Diamond MP, Saed GM. Advances in the pathogenesis of adhesion development: the role of oxidative stress. Reprod Sci Thousand Oaks Calif 2014;21:823–36.

96. Saed GM, Diamond MP. Molecular characterization of postoperative adhesions: the adhesion phenotype. J Am Assoc Gynecol Laparosc 2004;11:307–14.

97. Shavell VI, Saed GM, Diamond MP. Review: cellular metabolism: contribution to postoperative adhesion development. Reprod Sci Thousand Oaks Calif 2009;16:627–34.

98. Wiseman DM, Trout JR, Diamond MP. Effects of crystalloids on rates of adhesion development in abdominopelvic surgery. J Am Assoc Gynecol Laparosc 1998;5:S58.

99. Fletcher NM, Saed MG, Abuanzeh S, Abu-Soud HM, Al-Hendy A, Diamond MP, et al. Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod Sci Thousand Oaks Calif 2014;21:1145–52.

100. Fletcher NM, Awonuga AO, Abusamaan MS, Saed MG, Diamond MP, Saed GM. Adhesion phenotype manifests an altered metabolic profile favoring glycolysis. Fertil Steril 2016;105:1628–37.e1.

101. Fletcher NM, Awonuga AO, Neubauer BR, Abusamaan MS, Saed MG, Diamond MP, et al. Shifting anaerobic to aerobic metabolism stimulates apoptosis through modulation of redox balance: potential intervention in the pathogenesis of postoperative adhesions. Fertil Steril 2015;104:1022–9.

102. Fortin CN, Saed GM, Diamond MP. Predisposing factors to post-operative adhesion development. Hum Reprod Update 2015;21:536–51.

103. Tulandi T, Closon F, Czuzoj-Shulman N, Abenhaim H. Adhesion barrier use after myomectomy and hysterectomy: rates and immediate postoperative complications. Obstet Gynecol 2016;127:23–8.

104. Tulandi T, Agdi M, Zarei A, Miner L, Sikirica V. Adhesion development and morbidity after repeat cesarean delivery. Am J Obstet Gynecol 2009;201:56.e1–6.

105. Awonuga AO, Fletcher NM, Saed GM, Diamond MP. Postoperative adhesion development following cesarean and open intra-abdominal gynecological operations: a review. Reprod Sci 2011;18:1166–85.

106. Binda MM, Molinas CR, Mailova K, Koninckx PR. Effect of temperature upon adhesion formation in a laparoscopic mouse model. Hum Reprod 2004;19:2626–32.

107. Corona R, Verguts J, Koninckx R, Mailova K, Binda MM, Koninckx PR. Intraperitoneal temperature and desiccation during endoscopic surgery. Intraoperative humidification and cooling of the peritoneal cavity can reduce adhesions. Am J Obstet Gynecol 2011;205:392.e1–7.

108. Ott DE. Desertification of the peritoneum by thin-film evaporation during laparoscopy. JSLS 2003;7:189–95.

109. Ott DE. Laparoscopy and adhesion formation, adhesions and laparoscopy. Semin Reprod Med 2008;26:322–30.

110. Abuzeid OM, Raju R, Hebert J, Ashraf M, Abuzeid MI. A modified technique of temporary suspension of the ovary to the anterior abdominal wall. J Minim Invasive Gynecol 2018;25:26–7.

111. Chapa HO, Waters HC. Hospital cost savings associated with the use of an adhesion barrier during cesarean delivery. J Gynecol Surg 2012;28:207–11.

112. Roy S, Carlton R, Weisberg M, Clark R, Migliaccio-Walle K, Chapa H. Economic impact of the use of an absorbable adhesion barrier in preventing adhesions following open gynecologic surgeries. J Long Term Eff Med Implants 2015;25:245–52.